B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Executive Director - Head of Clinical Operations Excellence

Full-TimeUpdated on 10/23/2026
$271.8k - $351.8k/yr
Expert
Master's, PhD, Bachelor of Science (BS)
Remote in USA
RemoteRemote within the United States; travel up to 25%.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • At least 15 years of experience in the biotech, pharmaceutical, or contract research organization industry in a relevant field of clinical operations, clinical compliance, clinical monitoring, clinical trial management, or clinical quality assurance.
  • A Bachelor of Science degree in a scientific or healthcare discipline is required; advanced degrees are preferred.
  • Fluency in written and verbal English is required.
  • Experience building Good Clinical Practice quality systems and processes, including developing standard operating procedures and effective Corrective and Preventive Action programs.
  • Risk-based management skills and mindset.
  • Project management, root cause analysis, and Corrective and Preventive Action management skills.
  • Proficiency with Microsoft Word, Excel, Project, PowerPoint, and Outlook.
Responsibilities
  • Contribute to the development of Clinical Development and Global Clinical Operations strategies as a member of the Global Clinical Operations Leadership team, providing expertise in process, electronic Trial Master File management, quality, and compliance.
  • Lead the development, implementation, and maintenance of a proactive Good Clinical Practice compliance management infrastructure and processes, including clinical trial oversight, monitoring and quality control of key processes, standard operating procedures or work instructions, training, and change management.
  • Build and lead a team to improve infrastructure and systems.
  • Ensure adherence to regulatory requirements and Good Clinical Practice and pharmacovigilance guidelines through clinical performance indicators and innovative methods to improve processes.
  • Collaborate with Quality Assurance, Corporate Compliance, and Clinical Operations and Development colleagues to identify root causes of major and critical observations, develop corrective action plans, and follow up on their completion, implementation, and effectiveness.
  • Develop direct and indirect reports, including Clinical Study Managers and Clinical Research Associates.
  • Lead efforts to improve operational excellence in Clinical Development and Global Clinical Operations to support faster, high-quality clinical trials.
  • Participate in the development of Clinical Development and Global Clinical Operations strategies and provide expertise in quality, compliance, and operational excellence across clinical trial operations and partner functions.
  • Recommend ways for Global Clinical Operations programs to generate greater business value.
  • Lead end-to-end clinical trial oversight of standard operating procedures; develop, implement, and revise procedures; monitor compliance with procedures and policies; and ensure consistent adoption of operational processes, systems, and standards across trials.
  • Identify internal process improvements by monitoring key performance and quality indicators, ensure gaps are addressed to mitigate risk, and collaborate with Clinical Development functions as needed.
  • Explore and implement standardization and other methods to improve Clinical Operations excellence in collaboration with Clinical Development and Applied Innovation.
  • Develop training plans and programs across Global Clinical Operations and other clinical development functions, ensure knowledge is applied and retained, and monitor training compliance against corporate and organizational goals.
  • Develop, establish, and report clinical performance indicators related to quality and compliance, and provide performance and quality updates to senior Clinical Development leadership or the Executive Committee as needed.
  • Develop, implement, and maintain the Global Clinical Operations Compliance Management Plan, including electronic Trial Master File oversight; work with Clinical Quality Assurance to support compliance with Good Clinical Practice, standard operating procedures, and training requirements; monitor compliance risks; and prepare the organization for inspections.
  • Identify emerging compliance concerns, review relevant standard operating procedure deviations, conduct root cause analyses, and recommend solutions.
  • Ensure Corrective and Preventive Action assessments and resolutions are completed on time and appropriate actions are implemented for major and critical audit or inspection findings.
  • Oversee remedial and improvement plans arising from audits, inspections, or incidents, and follow up on their completion and implementation.
  • Maintain and optimize the electronic Trial Master File platform and leverage artificial intelligence to improve efficiency.
  • Establish standard operating procedures or work instructions, lead change management, and oversee team performance related to electronic Trial Master File processes.
  • Participate in inspection preparation and conduct.
  • Contribute to Clinical Operations and clinical trial sourcing strategy development and lead vendor due diligence.
  • Escalate issues to senior management in a timely manner.
  • Lead multifunctional, multinational teams to support quality conduct of clinical trials.
  • Manage internal staff and coordinate internal and external contractors or resources to maintain Good Clinical Practice compliance across field and global Clinical Operations functions.
  • Mentor and coach Global Clinical Operations teams as necessary.
Desired Qualifications
  • Knowledge of Mandarin.
  • Experience with Six Sigma, Lean, or Agile methodologies.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • Wellness Program
  • Paid Vacation

Growth & Insights and Company News

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.